Lumis International GmbH ads

I recently spoke with several MedTech founders—and a Notified Body—about the unique regulatory challenges of medical device software. The reality: Software intersects multiple complex frameworks (MDR, GDPR, and the AI Act). This makes a well-defined intended use and an iterative market entry approach more crucial than ever. Small, manageable steps are always better than getting lost in a regulatory maze. We recently published a new article on overcoming CE marking challenges for AIMD and SaMD, focusing on: -Managing Up-classification: Identifying exactly where your software or implant falls under current MDR rules. -Building Clinical Confidence: Bridging the gap between existing data and robust new evidence standards. -Holistic View: Navigating all applicable regulations seamlessly, not just the MDR. You can read the full article here: https://lnkd.in/erva4TCC Got any questions about your software strategy? Just reach out! Liam Spencer, Head of Regulatory Services #RegulatoryAffairs #MDR #AIMD #SaMD #MedTech #DigitalHealth #LumisInternational

Maintaining peace of mind in clinical trials is achieved through proactive management and meticulous oversight. Explore why Lumis’s oversight management provides the security and control you need to successfully run your clinical trials. https://lnkd.in/dKN7__7z

If you’re planning to conduct clinical trials in Europe as a sponsor outside the EU/EEA, there’s a legal requirement you simply cannot overlook: a legal representative within the EU/EEA. https://lnkd.in/dBWpT95T

Are you looking for expert legal representation to seamlessly navigate EU, UK, and Swiss clinical trial regulations? Then Lumis International is the solution—providing expert legal and data representation with audit-proven compliance to keep your global trials on track. Visit our website for full details on our legal representation services. https://lnkd.in/d9adqF6M Why "Expert Representation" is Critical: Legal Liability: A Legal Representative isn't just a mailbox; they are the point of contact for EU courts and authorities regarding safety, fraud, and non-compliance. Trial Acceleration: Solutions like the EY Clinical Trial Fast Lane focus on reducing site activation times (averaging 44–51 days), which is often the biggest bottleneck in development. Risk-Based Monitoring: 2026 regulations emphasize Quality by Design (QbD). Experts help move away from simple checklists to proactive risk-management strategies. We specialize in providing the expert legal support you need to ensure compliance and a smooth process. For any urgent inquiries, please contact us directly: https://lnkd.in/e52AfjTZ We are happy to help! Heike Schön, CEO Lumis International

Lumis International: EU Legal Representation for Swiss Biopharma. Expanding clinical trials from Switzerland into the EU? Under EU Clinical Trial Regulations, non-EEA sponsors must appoint an official EU Legal Representative. Already trusted by Swiss biopharma companies, Lumis International bridges the regulatory gap to the European market. Registered in Switzerland, we have handled legal representation and regulatory compliance for more than 10 years—saving you the time and expense of establishing EU subsidiaries. What Swiss Biopharma Sponsors Gain: -Cost Savings: Skip the expense of establishing foreign subsidiaries. -Fast Execution: 10-day average Legal Representative nomination timeline. -Zero-Risk Compliance: 100% success rate in client audits. -Proven Experience: Supporting trial sponsors since 2013 with a 47% client return rate. Expand into key European markets with total regulatory confidence. Book a 30-minute appointment with Lars Bak-Christensen for tailored advice. https://lnkd.in/egjHy4k7

What does a Legal Representative actually look like in practice when they assume legal liability for your trial in Europe? Under the EU CTR (536/2014), appointing an EEA-based representative is a strict requirement for non-EU sponsors. But it’s far more than a compliance checkbox—it directly impacts your timelines, CTIS submissions, and safety reporting across all countries. Lumis acts as your trusted legal representative across the EU/EEA, UK, and Switzerland, managing these complex legal proceedings so you can focus entirely on the successful performance of your clinical trial. Swipe through the slides below to learn more. Or visit: https://lnkd.in/d9adqF6M Have questions about legal representation for your European clinical trial? Connect with Heike Schoen, CEO of Lumis International, for an expert discussion on the best approach for your study.